Semaglutide Prices Drop in India After Generic Launches by Sun Pharma, Zydus, Dr Reddy’s; Check New Rates

India's semaglutide market has entered a new phase of competition, with prices falling steeply after more than 15 generic versions of the drug were introduced within just two days of patent expiry. The fresh launches are expected to widen access to treatment for patients living with type 2 diabetes and obesity, two conditions for which semaglutide has emerged as an important therapy in recent years.

Semaglutide Prices in India Drop After Patent Expiry as 15+ Generic Versions Launch

The rush of new launches has significantly altered pricing in the segment. According to Business Standard report, semaglutide prices in India have dropped by as much as 70% to 90% compared with innovator brands, marking one of the sharpest price corrections seen in a high-demand chronic therapy category.

The change is likely to draw attention from both patients and doctors, especially as cost has remained a key barrier to long-term treatment adherence.

What Is Semaglutide and Why Is It Used?

Semaglutide belongs to the class of GLP-1 agonists, or glucagon-like peptide-1 receptor agonists. These medicines help regulate blood sugar levels, increase the feeling of fullness, and slow down the rate at which food leaves the stomach.

Because of these effects, semaglutide is used in the management of type 2 diabetes and is also prescribed in certain cases for weight management in people with obesity or related metabolic risks.

Its role in treatment has gained prominence because it addresses more than one metabolic concern at the same time. In patients with type 2 diabetes, it helps improve glucose control, while in obesity management, it supports appetite regulation and weight reduction under medical supervision.

Patent Expiry Opens Door for Generic Wave

The launch momentum picked up immediately after the original molecule lost patent protection in India. Within a day, several domestic pharmaceutical companies moved to introduce their own lower-cost versions, rapidly expanding the choices available in the market. The development has effectively turned semaglutide into a more competitive category, with multiple brands now vying for a place in diabetes and obesity treatment.

India's Rs 1,446 crore GLP-1 agonist market is therefore poised for a major shift, as generic competition is expected to improve affordability and deepen market penetration. With at least 15 to 16 versions already launched or introduced in quick succession, the category is seeing a rare burst of activity in a very short period.

Sun Pharma, Zydus, Dr Reddy's, Natco Launch Generic Semaglutide in India; Check Prices

Sun Pharma Launches Noveltreat and Sematrinity Under Rs 2,000

Among the major companies entering the space, Sun Pharma has launched semaglutide under two separate brand names. Noveltreat has been positioned for long-term weight management and is available in five dose strengths. Sematrinity, meanwhile, has been introduced for patients whose type 2 diabetes is not adequately controlled.

The weekly treatment cost for Noveltreat ranges from around Rs 900 to Rs 2,000, while Sematrinity is priced at about Rs 750 to Rs 1,300 per week.

Zydus Lifesciences' SEMAGLYN, MASHEMA and ALTERME

Zydus Lifesciences has also entered the segment with its semaglutide offering, using a reusable multi-dose pen device. The drug is being marketed under the brand names SEMAGLYN, MASHEMA and ALTERME. The company has said the average monthly treatment cost for its product will be around Rs 2,200.

Dr Reddy's Launches Obeda

Dr Reddy's Laboratories has launched Obeda, which it has described as India's first DCGI-approved generic semaglutide injection for type 2 diabetes. The product is available in 2 mg and 4 mg strengths and is priced at about Rs 4,200 per month.

Although priced above some of the newer competing offerings, Obeda adds another major name to the growing list of domestic semaglutide brands and expands the treatment menu for prescribers and patients.

Natco Pharma

Before the latest wave of launches by other large drugmakers, Natco Pharma had already introduced a similar semaglutide product.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.